Aptinyx Inc. (APTX)
Company Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.
The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.
It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment.
The company has a research collaboration agreement with Allergan plc.
Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
| Country | United States |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Craig R. Jalbert CIRA |
Contact Details
Address: 909 Davis Street Evanston, Illinois United States | |
| Website | https://www.aptinyx.com |
Stock Details
| Ticker Symbol | APTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001674365 |
| CUSIP Number | 03836N103 |
| ISIN Number | US03836N1037 |
| Employer ID | 47-4626057 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ashish Khanna | Chief Financial Officer & Chief Bus. Officer |
| Dr. Andrew D. Kidd B.M. B.Ch., M.D. | Interim Principal Executive Officer, Principal Financial Officer & Principal Accounting Officer |
| Dr. Harald Murck M.D., Ph.D. | Vice President of Clinical & Medical Affairs |
| Dr. Kathryn King Ph.D. | Senior Vice President of Clinical & CMC Operations |
| Dr. Norbert G. Riedel | Executive Chairman |
| Molly Dir | Vice President of Human Resources |
| Patrick Flavin | Senior Manager of Corporate Development & Investor Relations |
| Tim Noffke | Vice President of Program Management & Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 09, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Dec 21, 2023 | 8-K | Current Report |
| Dec 18, 2023 | 8-K | Current Report |
| Jul 10, 2023 | 25-NSE | Filing |
| Jul 03, 2023 | 8-K | Current Report |
| Jun 27, 2023 | SC 13D/A | [Amend] Filing |
| Jun 02, 2023 | DEF 14A | Filing |
| May 24, 2023 | S-8 POS | Filing |
| May 24, 2023 | S-8 POS | Filing |
| May 24, 2023 | S-8 POS | Filing |